BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26214180)

  • 1. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.
    Tachi Y; Hirai T; Toyoda H; Tada T; Hayashi K; Honda T; Ishigami M; Goto H; Kumada T
    PLoS One; 2015; 10(7):e0133515. PubMed ID: 26214180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.
    Wang CC; Liu CH; Lin CL; Wang PC; Tseng TC; Lin HH; Kao JH
    J Formos Med Assoc; 2015 Oct; 114(10):923-8. PubMed ID: 26279173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring.
    Elesawy BH; Abd El Hafez A; Dorgham LS; El-Askary A
    Pathol Res Pract; 2014 Dec; 210(12):922-8. PubMed ID: 25123964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?
    Cheung RC; Currie S; Shen H; Bini EJ; Ho SB; Anand BS; Hu KQ; Wright TL; Morgan TR;
    J Clin Gastroenterol; 2008 Aug; 42(7):827-34. PubMed ID: 18285716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis.
    Kayadibi H; Yasar B; Ozkara S; Serdar MA; Kurdas OO; Gonen C
    Scand J Clin Lab Invest; 2014 Apr; 74(3):240-7. PubMed ID: 24460024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection].
    González Guilabert MI; Hinojosa Mena-Bernal C; del Pozo González J; del Pozo Pérez MA
    Gastroenterol Hepatol; 2010; 33(6):425-32. PubMed ID: 20471720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection.
    Carvalho-Filho RJ; Schiavon LL; Narciso-Schiavon JL; Sampaio JP; Lanzoni VP; Ferraz ML; Silva AE
    Liver Int; 2008 Apr; 28(4):486-93. PubMed ID: 18339075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of three non-invasive markers in assessing the severity of liver fibrosis in chronic hepatitis C.
    Shaikh S; Memon MS; Ghani H; Baloch GH; Jaffery M; Shaikh K
    J Coll Physicians Surg Pak; 2009 Aug; 19(8):478-82. PubMed ID: 19651008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
    Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
    J Viral Hepat; 2012 Feb; 19(2):e97-104. PubMed ID: 22239532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
    Dinesen L; Caspary WF; Chapman RW; Dietrich CF; Sarrazin C; Braden B
    Dig Liver Dis; 2008 Sep; 40(9):743-8. PubMed ID: 18339592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acoustic radiation force impulse elastography and serum fibrosis markers in chronic hepatitis C.
    Silva Junior RG; Schmillevitch J; Nascimento Mde F; Miranda ML; Brant PE; Schulz PO; Vieira A; Szutan LA
    Scand J Gastroenterol; 2014 Aug; 49(8):986-92. PubMed ID: 24742130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of liver fibrosis among injection drug users with chronic hepatitis C.
    Wilson LE; Torbenson M; Astemborski J; Faruki H; Spoler C; Rai R; Mehta S; Kirk GD; Nelson K; Afdhal N; Thomas DL
    Hepatology; 2006 Apr; 43(4):788-95. PubMed ID: 16557548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
    Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
    Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The validity of serum markers for fibrosis staging in chronic hepatitis B and C.
    Li J; Gordon SC; Rupp LB; Zhang T; Boscarino JA; Vijayadeva V; Schmidt MA; Lu M;
    J Viral Hepat; 2014 Dec; 21(12):930-7. PubMed ID: 24472062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.
    Lin ZH; Xin YN; Dong QJ; Wang Q; Jiang XJ; Zhan SH; Sun Y; Xuan SY
    Hepatology; 2011 Mar; 53(3):726-36. PubMed ID: 21319189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
    Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
    Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.